Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 6/20 | 0.73 |
| ▸ | IGF1R | P08069 | 14/20 | 0.51 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | RAF1 | P04049 | 1/20 | 0.51 |
| ▸ | INSR | P06213 | 1/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1129273 | 1.00 | TNK2 (0.73) | TNK2IGF1RPDPK1ABL1EGFR | |
| SCHEMBL1129225 | 0.90 | TNK2 (0.62) | TNK2IGF1RPDPK1ABL1EGFR | |
| SCHEMBL1129391 | 0.85 | TNK2 (1.00) | TNK2IGF1R | |
| SCHEMBL1129393 | 0.85 | TNK2 (1.00) | TNK2IGF1R | |
| SCHEMBL3172098 | 0.84 | IGF1R (0.53) | TNK2IGF1RPDPK1ABL1EGFR | |
| SCHEMBL3172083 | 0.84 | IGF1R (0.53) | TNK2IGF1RPDPK1ABL1EGFR | |
| SCHEMBL6934441 | 0.83 | IGF1R (0.78) | TNK2IGF1RPDPK1ABL1EGFR | |
| SCHEMBL8399665 | 0.82 | TNK2 (0.63) | TNK2IGF1RPDPK1ABL1EGFR | |
| SCHEMBL593894 | 0.82 | IGF1R (0.51) | TNK2IGF1R | |
| SCHEMBL1129237 | 0.80 | TNK2 (1.00) | TNK2IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481733-B2 | Substituted imidazopyr- and imidazotri-azines | OSI Pharmaceuticals, LLC (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2283020-B1 | SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES | OSI PHARM INC (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2283020-A1 | SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES | OSI Pharmaceuticals, Inc. (US) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009143051-A1 | SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES | OSI PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090286768-A1 | SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES | OSI PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286768-A1 | SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES | ABL1, TPMT, CYP2C19 | TNK2 2837/4885IGF1R 138/4885PDPK1 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.